ライフサイエンスコーパス: pulsatile flow

1 and perfused with blood under high-pressure pulsatile flow.

2 ieties and EC was assessed after exposure to pulsatile flow.

3 or steady flow (89.6+/-2.7% of AOA) than for pulsatile flow (76.3+/-5.0% of AOA).

4 that recognition of systolic flow reversal (pulsatile flow) after thrombolytic administration on cor

5 vity was not different between patients with pulsatile flow and controls (P=0.34).

6 y(glycerol sebacate) (PGS) and cultured in a pulsatile flow bioreactor for 3 wk.

7 y into breathing circuits with intermittent (pulsatile) flow can lead to streaming and tidal pooling

8 A pulsatile flow circuit was used to perfuse arterial segm

9 for gravity-driven, integrated, microfluidic pulsatile flow circuits.

10 ure of embryonic valve tissue under specific pulsatile flow conditions.

11 r rates (8 to 12 dynes/cm2) occurred only in pulsatile flow conditions.

12 When cultured under pulsatile flow, developing valve tissues upregulated fib

13 ice (134 patients) or the currently approved pulsatile-flow device (66 patients).

14 2 700 per quality-adjusted life year for the pulsatile-flow device.

15 y has improved significantly relative to the pulsatile flow devices.

16 recovery was noted in patients treated with pulsatile flow devices.

17 ients with continuous-flow devices than with pulsatile-flow devices (62 of 134 [46%] vs. 7 of 66 [11%

18 are smaller and may be more durable than the pulsatile-flow devices.

19 In contrast, pulsatile flow downregulated both gp91phox and Nox4 mRNA

20 racterize the viscoelastic behavior, and the pulsatile flow frequency (f) has been investigated.

21 Nonreversing pulsatile flow, generally considered protective of ather

22 Patients with pulsatile flow had a higher risk of death or reinfarctio

23 nd DT (n = 638) and 114 DT patients with the pulsatile flow HeartMate XVE (Thoratec Corporation).

24 es compared with patients implanted with the pulsatile-flow HeartMate XVE.

25 nding or circumflex) (p = 0.02, p < 0.0001), pulsatile flow (i.e., reversal of flow in systole, a mar

26 h temporal resolution to resolve the dynamic pulsatile flow in collecting lymphatic vessels.

27 siological effects of the chronic absence of pulsatile flow in humans.

28 gned to mimic the human heart by producing a pulsatile flow in parallel with the patient's heart, new

29 Subjecting endothelial cells to pulsatile flow in the presence of the ADAM10 inhibitor c

30 Normal pulsatile flow is lost or markedly attenuated after Font

31 quality of life when treated with implanted pulsatile-flow left ventricular assist devices as compar

32 he risk of 90-day in-hospital mortality with pulsatile flow LVAD as destination therapy (DT).

33 In the first era, mortality of pulsatile-flow LVAD patients was higher than in status 2

34 nuous-flow LVAD are smaller and quieter than pulsatile-flow LVADs.

35 urgency status 1A, 1B, and 2; patients with pulsatile-flow LVADs; and patients with continuous-flow

36 and mechanical properties were assessed in a pulsatile flow model.

37 y pulsatile flow of the venous system to the pulsatile flow of the arterial circulation is a minor mi

38 genic tone, from the low-pressure, minimally pulsatile flow of the venous system to the pulsatile flo

39 icant sex difference in mortality for either pulsatile-flow (P=0.82) or continuous-flow (P=0.95) devi

40 of slower nonculprit artery flow included a pulsatile flow pattern (i.e., systolic flow reversal) in

41 e culprit artery, the duration of patency, a pulsatile flow pattern and thrombus are also related to

42 configuration, using both a continuous and a pulsatile flow pattern, and collected in a water-seal sp

43 59, blocking ERK1/2) blocked or reversed the pulsatile-flow pH(i) change to acidification.

44 ge-vessel phantoms were constructed, using a pulsatile flow pump, and absolute diameter and percentag

45 ation, epicardial flow, and creatine kinase, pulsatile flow remained associated with an increased ris

46 Switching from steady to pulsatile flow (same man flow) resulted in a small, albe

47 the absence but not in the presence of ECs, pulsatile flow significantly increased the migration of

48 Pulsatile flow (systolic flow reversal with cessation of

49 iderably larger for steady and non-reversing pulsatile flow than for oscillatory flow.

50 r in ECs exposed to physiologically relevant pulsatile flow than pathophysiologically relevant oscill

51 all the grafts, but after 6 h of exposure to pulsatile flow the RGD/Hep-bonded graft had a significan

52 This was tested in vitro with steady and pulsatile flow through 0.07- to 0.8-cm(2) orifices and i

53 ntricular assist devices, the restoration of pulsatile flow through modulations in pump speed leads t

54 ught to determine whether the restoration of pulsatile flow through modulations in pump speed would r

55 d by atherosclerotic plaque rupture, complex pulsatile flows through stenotic regions producing high

56 nism for low-density particles in steady and pulsatile flows through T-shaped junctions.

57 A novel Pulsatile-Flow Ventilation (PFV) system reducing respira

58 ial-flow ventricular assist devices, and (5) pulsatile-flow ventricular assist devices.

59 Pulsatile flow was associated with higher corrected TIMI

60 , whereas passing WSS at peak systole of the pulsatile flow waveform does.

61 ative number of leukocyte TEM as compared to pulsatile flow, whereas passing WSS at peak systole of t

62 microg/mL of native LDL were exposed to (1) pulsatile flow with a mean shear stress (tau(ave)) of 25